Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 29, 2018
Event: Regulation FD Disclosure regarding FDA approval of a new product.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the United States Food and Drug Administration (FDA) approval of BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg. Key details include:
- Product Status: First and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule.
- Indication: Treatment of moderate to severe vasomotor symptoms (hot flashes or flushes) due to menopause in women with a uterus.
Guidance, Outlook, and Management Commentary
Management Actions:
- The Company issued a press release (Exhibit 99.1) announcing the approval.
- A conference call was hosted on October 29, 2018, at 8:30 a.m. EDT to discuss the approval.
- An investor presentation (Exhibit 99.2) was furnished for use in meetings with investors or analysts.
Investor Verification Checklist
- Verify the commercial launch timeline and distribution strategy for BIJUVA™.
- Review the full text of the press release (Exhibit 99.1) for specific market positioning details.
- Examine the investor presentation (Exhibit 99.2) for any updated financial projections or sales targets.
- Confirm the competitive landscape for bio-identical hormone therapies following this approval.